Emyria Ltd

Emyria Ltd

EMD · AU · Healthcare / Health Information Services

0.037AUD-0.00 (-2.63%)

Price History

Full chart

Market Stats

Previous Close0.038
Open0.037
Day Range0.037 – 0.038
52-Week Range0.036 – 0.078
Volume342.49K
Market Cap36.30M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta0.03
50-Day Avg0.0471
200-Day Avg0.0479

About

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the expand Emyria's MDMA analogue drug development program. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Subiaco, Australia.

Company Details

  • SectorHealthcare
  • IndustryHealth Information Services
  • CEOMr. Gregory Hutchinson
  • Employees0
  • HeadquartersLevel 1, 516 Hay Street, Subiaco, WA, Australia, 6008, Australia
  • Websitehttps://emyria.com

Leadership

  • Mr. Gregory HutchinsonExecutive Chairman
  • Dr. Michael WinloChief Scientific Officer & Executive Director
  • Mr. Joseph Daniel Ohayon ACA, MBA Intl Bus.Chief Financial Officer
  • Dr. Alistair VickeryExecutive Medical Director & Director
  • Mary-Ann RennieHead of Corporate Operations
  • Ms. Susan Patricia Park A.C.A., A.C.I.S., ACSA, AGIA, B.Com., C.A., F FinCompany Secretary · b. 1975

Financials

Income Statement

Currency: AUD2018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue0109.91K1.01M1.98M1.82M1.59M2.20M1.39M3.88M
Growth (%)--+822.08%+94.97%-7.77%-12.62%+38.32%-36.68%+178.16%
Cost of Revenue-1.73M3.80M3.56M6.24M4.91M2.37M1.37M7.54M
Gross Profit--1.62M-2.79M-1.58M-4.41M-3.32M-167.55K24.48K-3.66M
Gross Margin--1470.68%-275.00%-80.20%-242.22%-208.56%-7.61%1.76%-94.31%
Operating Expense-1.09M2.84M4.13M4.12M3.80M6.74M2.67M2.61M
Operating Income-64.32K-2.71M-5.63M-5.71M-8.54M-7.12M-6.90M-2.65M-6.27M
Operating Margin--2463.52%-555.64%-289.02%-468.52%-446.97%-313.37%-189.66%-161.58%
EBITDA-64.32K-2.58M-4.80M-4.49M-8.03M-6.69M-13.03M-2.39M-5.81M
EBITDA Margin--2351.07%-473.14%-227.47%-440.50%-420.19%-591.76%-171.56%-149.78%
Net Income-64.34K-2.68M-5.24M-4.91M-7.33M-5.13M-11.46M-3.14M-6.11M
Net Income Margin--2441.04%-516.85%-248.30%-402.09%-322.21%-520.07%-225.33%-157.60%
R&D221.49K221.49K1.51M2.62M2.21M1.80M2.09M812.23K531.13K
R&D as % of Total Revenue-201.52%148.52%132.54%121.21%112.94%94.74%58.23%13.69%
Interest Expense604.04K59.54K66.85K72.22K128.79K253.31K134.56K61.25K
Interest Expense % of Total Revenue-3.68%5.88%3.38%3.96%8.09%11.50%9.65%1.58%

Balance Sheet

Currency: AUD2018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets3.06M3.52M5.06M9.06M8.25M10.16M5.43M6.62M11.49M
Total Liabilities250.43K3.03M1.28M1.88M1.93M3.37M3.00M1.31M2.65M
Total Equity2.81M499.54K3.78M7.18M6.32M6.79M2.43M5.31M8.85M
Cash3.04M2.61M3.69M6.53M3.88M2.73M1.57M3.57M7.29M
Total Debt-3.15M610.82K949.70K632.71K1.27M1.72M613.50K787.38K
Net Debt-3.04M513.14K-3.08M-5.58M-3.25M-1.46M152.47K-2.96M-6.50M

Cash Flow

Currency: AUD2018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-20.82K-2.59M-4.45M-3.94M-5.43M-3.77M-4.28M-2.70M-4.56M
Investing Cash Flow-901.06K-901.06K-201.81K-661.39K-2.03M-3.23M-1.38M81.07K-546.59K
Financing Cash Flow3.06M3.11M5.73M7.44M4.81M5.86M4.50M4.63M8.82M
Capital Expenditure844.80K844.80K201.81K661.39K2.03M3.23M159.10K13.89K366.16K
Free Cash Flow-20.82K-3.44M-4.65M-4.60M-7.46M-7.01M-4.44M-2.72M-4.92M
Dividends Paid--527.36K341.83K767.73K62.62K---
FCF to OCF100.00%132.58%104.53%116.80%137.38%185.74%103.71%100.51%108.03%
Dividend Paid to FCF---11.33%-7.43%-10.30%-0.89%---

Earnings

Report DateFeb 28, 2020Aug 31, 2020Feb 24, 2021Aug 31, 2021Feb 28, 2022Aug 29, 2022Feb 27, 2023Feb 26, 2025Aug 27, 2025
EPS Estimate0.000.000.00----0.000.00
EPS Actual-0.01-0.02-0.01-0.01-0.01-0.01-0.010.000.00
Surprise---------
Timing----Pre-marketAfter-hoursPre-marketAfter-hours-

Key Statistics & Ratios

Market Cap36.30M
Enterprise Value34.63M
Trailing P/E0.00
Forward P/E0.00
Price / Sales8.96
Price / Book4.65
EPS-0.01
Book Value0.011
Revenue (TTM)4.05M
Gross Profit (TTM)919.33K
EBITDA-4.91M
Profit Margin-150.84%
Operating Margin-122.83%
Return on Equity-86.42%
Return on Assets-34.65%
Shares Outstanding806.69M
Shares Float591.22M
Beta0.03
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%